Minute Insights: Helio Health CEO Launces AI-backed Liver Cancer Diagnostic
Following Helio’s recent launch of the HelioLiver liver cancer diagnostic, Medtech Insight spoke to the company’s CEO to find out how the company is using artificial intelligence to improve diagnostics.
You may also be interested in...
The company expects the major commercial collaboration and geographical roll-out will lead to increased adoption of Agendia’s breast cancer diagnostics.
The annual J.P. Morgan Healthcare Conference includes presentations from major medtech companies describing their experience in 2021 and expectations for 2022. Here are some highlights from the in vitro diagnostics companies that presented on the first two days of the meeting.
Medtech Insight spoke to Rutger Zietsma, Manus Neurodynamica’ CEO, to learn about the next commercial steps for the company's Neuromotor Pen for differential diagnosis of neuromotor impairment.